Please wait while the formulary information is being retrieved.
TADLIQ (tadalafil)
- pulmonary arterial hypertension
20 mg/5 mL (4 mg/mL) oral suspension
- 10 milliliters (40 mg) by oral route once daily
Default screening record
- 5 milliliters (20 mg) by oral route once daily
- 10 milliliters (40 mg) by oral route once daily
- Adempas
- Bidil
- boceprevir
- Dilatrate-sr
- Imdur
- Incivek
- Isochron
- Isoditrate
- isosorbide dinitrate
- isosorbide mononitrate
- isosorbide-hydralazine
- Minitran
- Nithiodote
- Nitro-bid
- Nitro-dur
- Nitro-time
- nitroglycerin
- nitroglycerin in 5 % dextrose
- Nitrolingual
- Nitromist
- Nitropress
- nitroprusside
- Nitrostat
- riociguat
- sodium nitrite
- sodium nitrite-sod thiosulfate
- telaprevir
- Victrelis
Contraindicated
- None
Severe
Moderate
- alfuzosin
- Cardura
- Cardura Xl
- Dibenzyline
- doxazosin
- dutasteride-tamsulosin
- Flomax
- Jalyn
- Minipress
- phenoxybenzamine
- phentolamine
- prazosin
- tamsulosin
- terazosin
- Uroxatral
- Child-pugh class C hepatic impairment
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Chronic kidney disease stage 5 (failure) GFr<15 ml/min
Contraindicated
- Alcohol intoxication
- Anterior ischemic optic neuropathy
- Aortic valve stenosis
- Cerebrovascular accident
- Child-pugh class A hepatic impairment
- Child-pugh class B hepatic impairment
- Chronic heart failure
- Chronic kidney disease stage 2 (mild) GFR 60-89 ml/min
- Chronic kidney disease stage 3A (moderate) GFR 45-59
- Chronic kidney disease stage 3B (moderate) GFR 30-44
- Fibrosis of corpus cavernosum
- Hypertrophic cardiomyopathy
- Hypotension
- Life-threatening cardiac arrhythmias
- Penile angulation
- Peptic ulcer
- Peyronie's disease
- Pigmentary retinopathy
- Restrictive cardiomyopathy
- Severe uncontrolled hypertension
- Unstable angina pectoris
Severe
Moderate
- Hearing loss
- Increased risk of bleeding
- Increased risk of bleeding due to coagulation disorder
- Kidney disease with likely reduction in GFR
- Leukemia
- Multiple myeloma
- Seizure disorder
- Sickle cell disease
TADLIQ (tadalafil)
- pulmonary arterial hypertension
- None
- Headache disorder
More Frequent
Severe
Less Severe
- None
- Acute abdominal pain
- Back pain
- Cough
- Diarrhea
- Dyspepsia
- Flushing
- Gastroesophageal reflux disease
- Myalgia
- Nasal congestion
- Nausea
- Pain in extremities
- Pharyngitis
- Upper respiratory infection
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Acute myocardial infarction
- Angina
- Anterior ischemic optic neuropathy
- Blurred vision
- Cerebrovascular accident
- Chest pain
- Conjunctivitis
- Dysphagia
- Dyspnea
- Esophagitis
- Exfoliative dermatitis
- Facial edema
- Hearing loss
- Hypertension
- Hypotension
- Kidney disease with reduction in GFR
- Orthostatic hypotension
- Palpitations
- Priapism
- Rectal bleeding
- Retinal vascular occlusion
- Seizure disorder
- Stevens-johnson syndrome
- Syncope
- Tachycardia
- Vision loss
- Visual field defect
Less Severe
- Acquired chromatopsia
- Arthralgia
- Conjunctival hyperemia
- Dizziness
- Drowsy
- Epistaxis
- Eye tearing
- Eyelid edema
- Fatigue
- Frequent erections
- Gastritis
- General weakness
- Hyperhidrosis
- Hypoesthesia
- Insomnia
- Loose stools
- Migraine
- Neck pain
- Ocular pain
- Pain
- Paresthesia
- Peripheral edema
- Pruritus of skin
- Skin rash
- Tinnitus
- Transient global amnesia
- Urticaria
- Vertigo
- Visual changes
- Vomiting
- Xerostomia
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Tadalafil
No efficacy demonstrated in trials of Duchenne muscular dystrophy. Not indicated in pediatrics.
- 1 Day – 18 Years
- No efficacy demonstrated in trials of Duchenne muscular dystrophy. Not indicated in pediatrics.
Tadalafil
- Severity Level:
2
- Additional Notes: Insufficient human data available
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Tadalafil
Insufficient human data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Tadalafil
Hepatic-Use caution with hepatic impairment. Renal-Adjust dose for moderate to severe renal impairment.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | Y | Y | Y | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Pulmonary arterial hypertension | |
| I27.0 | Primary pulmonary hypertension |
| I27.21 | Secondary pulmonary arterial hypertension |
| 0-9 | A-Z |
|---|---|
| I27.0 | Primary pulmonary hypertension |
| I27.21 | Secondary pulmonary arterial hypertension |
Formulary Reference Tool